| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
- |
| Employees |
48 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
0 |
| Cash Flow (TTM) (Millions $) |
35 |
| Capital Exp. (TTM) (Millions $) |
0 |
Alterity Therapeutics Limited
Alterity Therapeutics Limited is a biotechnology company that focuses on developing innovative therapeutics for neurodegenerative diseases. The company's primary focus is on Parkinson's disease and other related disorders, such as Multiple System Atrophy and Alzheimer's disease.
Alterity Therapeutics is known for their unique approach to drug development, which involves targeting the abnormal accumulation of iron in the brain. Their lead drug candidate, PBT434, has shown promising results in preclinical studies and is currently being evaluated in clinical trials for Parkinson's disease.
The company is dedicated to advancing the understanding of neurodegenerative diseases and improving the lives of patients through the development of safe and effective treatments. Alterity Therapeutics collaborates with leading academic institutions and research organizations to accelerate their drug discovery and development programs.
Alterity Therapeutics Limited is headquartered in Melbourne, Australia, and is listed on the Australian Securities Exchange (ASX: ATH).
Company Address: Level 14, 350 Collins Street Melbourne 3000
Company Phone Number: 3 9349 4906 Stock Exchange / Ticker: NASDAQ ATHE
|
3.04% 